{"entity":{"id":"turnstone-biologics","kind":"company","name":"Turnstone Biologics","aka":[],"tldr":"Turnstone developed 'selected' tumour-infiltrating lymphocyte therapy, enriching the most cancer-reactive immune cells from a patient's tumour. It stopped its clinical programme in January 2025 and was bought by XOMA Royalty later that year.","summary":"Turnstone Biologics was a San Diego biotechnology company that pioneered selected tumour-infiltrating lymphocyte (Selected TIL) therapy, enriching TIL populations for tumour reactivity. Its lead programme TIDAL-01 was studied in solid tumours and clinical data were presented at the SITC TIL Symposium in November 2024. In January 2025 the company discontinued all TIDAL-01 studies and halted development, then began a strategic alternatives process. On 27 June 2025 Turnstone agreed to be acquired by XOMA Royalty Corporation for $0.34 in cash per share plus a contingent value right; the tender offer and merger completed on 11 August 2025 and the Nasdaq listing (TSBX) ended. The company website no longer resolves.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.sec.gov/edgar/browse/?CIK=0001764974"},{"label":"XOMA acquisition agreement (8-K, June 2025)","url":"https://www.sec.gov/Archives/edgar/data/1764974/000119312525151306/d928306dex991.htm"},{"label":"Completion of merger (8-K, August 2025)","url":"https://www.sec.gov/Archives/edgar/data/1764974/000119312525177597/d27108d8k.htm"},{"label":"Q4 2024 results noting TIDAL-01 discontinuation (8-K)","url":"https://www.sec.gov/Archives/edgar/data/1764974/000095017025047107/tsbx-ex99_1.htm"},{"label":"SEC EDGAR filings","url":"https://www.sec.gov/edgar/browse/?CIK=0001764974"}],"tags":[],"related":[],"cancers":[],"sections":["cell-therapy"],"technologies":["til-therapy"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Former Nasdaq ticker TSBX. IPO (2023) not sourced."],"hq":"San Diego, CA","country":"US","companyType":"cell-therapy","stage":"acquired","investors":[],"funding":[{"round":"Acquisition","year":2025,"source":"https://www.sec.gov/Archives/edgar/data/1764974/000119312525151306/d928306dex991.htm","note":"$0.34 in cash per share plus a contingent value right; agreement 27 June 2025, merger completed 11 August 2025"}]},"route":"/companies/turnstone-biologics/","neighbours":{"section":[{"id":"cell-therapy","kind":"section","name":"Cell Therapy","route":"/fronts/cell-therapy/"}],"technology":[{"id":"til-therapy","kind":"technology","name":"TIL therapy","route":"/technologies/til-therapy/"}]}}